OpenAlex
PricingAboutJobs
Log inGet started
Work

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

HTML

Year: 2011
Type: article
Source: The Lancet Neurology
DOI: 10.1016/s1474-4422(11)70023-0
Authors: Gavin Giovannoni, Stuart Cook, Kottil Rammohan, Peter Rieckmann, Per Soelberg Sørensen, Patrick Vermersch, Anthony Hamlett, Vissia Viglietta, Steven Greenberg
Institutions: Queen Mary University of London, Blizard Institute, Rutgers New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Copenhagen University Hospital, Rigshospitalet, Université Lille Nord de France, Merck Serono S.A. (Switzerland)
Language: English

Topic: Multiple Sclerosis Research Studies
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Keywords: relapsing-remitting multiple sclerosis, cladribine tablets, disease activity, relapse prevention, disability progression, gadolinium-enhancing lesions, T2 lesion volume, highly active disease, CLARITY trial, subgroup analysis, dose comparison, oral disease-modifying therapy
SDG: Good health and well-being

Open Access status: closed

Funders: Novartis, Roche, Acumed
OpenAlex ID: W2107424415
FWCI: 10.87
Cites: 34
Cited by: 276
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms